Clinical Trials Logo

C Hepatitis, Tri Therapy clinical trials

View clinical trials related to C Hepatitis, Tri Therapy.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01716403 Terminated - Clinical trials for C Hepatitis, Tri Therapy

Telaprevir Exposure and Severe Anemia in HCV Infected Patients Treated by Tri-therapy

Ribatela
Start date: October 2012
Phase: N/A
Study type: Observational

The risk of severe anemia is increased in patients treated by tri-therapy compared to patients treated by bitherapy. The underlying mechanisms involved in this toxicity remain unexplored but could also depend on the global exposure of telaprevir. The trough concentration or AUC of telaprevir could therefore be a predictive factor of the onset of anemia in patients treated by ribavirin/PEG-INF/telaprevir. The early measurement of telaprevir and ribavirin concentrations could help to manage HCV tri-therapy to improve tolerance and SVR.